CTLA4 and glioblastoma: Although several preclinical studies have achieved optimal ORR in glioblastoma mouse models with antibodies targeting PD-1/PD-L1, CTLA-4, TIM-3 LAG-3, IDO, or OX-40 [20, 34, 74, 77], there is still a long time period before these strategies are approved for clinical use.